PHARMACOKINETICS OF CARBOPLATINUM IN SERUM AND INTRAPERITONEAL-FLUID AFTER INTRAPERITONEAL ADMINISTRATION

被引:4
作者
CZEJKA, M
JAGER, W
SCHULLER, J
TEHERANI, D
机构
[1] KRANKENANSTALT RUDOLFSTIFTUNG WIEN,ONKOL ABT,A-1030 VIENNA,AUSTRIA
[2] OSTERREICH FORSCHUNGSZENT SEIBERSDORF GMBH,INST BIOL,A-2444 SEIBERSDORF,AUSTRIA
关键词
D O I
10.1002/ardp.19913240310
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The concentration-profile of the antineoplastic agent carboplatinum in serum and intraperitoneal-fluid (IPF) of six female patients was studied. Pharmaco-kinetical analysis showed a rapid distribution-phase between both compartments within the first 4 h after administration (t1/2 serum = 4.4 h, t1/2 IPF = 3.3 h). Elimination half-life of carboplatinum of 20.3 h from the blood-vessel-system was significantly higher than from the intraperitoneal-compartment (t1/2 = 10.6 h). The relative bioavailability (calculated as AUC-values) was at least 6 times higher for the IPF than for serum within the first 48 h. 98% of measured amount were eliminated from both compartments within this time. The desired high IPF-levels support this route of administration.
引用
收藏
页码:183 / 184
页数:2
相关论文
共 5 条
  • [1] DEGREGORIO MW, 1986, CANCER CHEMOTH PHARM, V18, P235
  • [2] INTRAPERITONEAL CISPLATIN WITH SYSTEMIC THIOSULFATE PROTECTION
    HOWELL, SB
    PFEIFLE, CL
    WUNG, WE
    OLSHEN, RA
    LUCAS, WE
    YON, JL
    GREEN, M
    [J]. ANNALS OF INTERNAL MEDICINE, 1982, 97 (06) : 845 - 851
  • [3] PHASE-I STUDY AND PHARMACOKINETICS OF INTRAPERITONEAL CARBOPLATIN
    MCVIE, JG
    HUININK, WT
    DUBBELMAN, R
    FRANKLIN, H
    VANDERVIJGH, W
    KLEIN, I
    [J]. CANCER TREATMENT REVIEWS, 1985, 12 : 35 - 41
  • [4] VERMORKEN JB, 1984, CANCER TREAT REP, V68, P505
  • [5] YAMADA K, 1989, JPN SOC HOSP PHARM, V25, P325